Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Cytokinetics Inc (CYTK) Price & Performance

State Street SPDR Bloomberg 1-3 Month T-Bill ETFTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Cytokinetics Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Cytokinetics Inc trades at $76.53 (market cap $10.63B). The key difference: Cytokinetics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.

BILCYTK
Sector
Fixed IncomeTechnology
52-Week High
$91.77$87.26
52-Week Low
$91.27$34.31
Market Cap
$10.63B
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL, the SPDR Bloomberg 1-3 Month T-Bill ETF, trades at $91.50, up 0.02% on the day, with a bearish technical signal from moving averages. The fund provides exposure to short-term U.S. Treasury bills, with recent institutional buying activity noted. Key support and resistance cluster around $91, while the relative strength index at 21.69 indicates potential oversold conditions.

The outlook for BIL is influenced by Federal Reserve policy expectations and Treasury yield movements. Rising yields may pressure returns, but the fund offers a low-risk cash alternative. Risks include interest rate volatility and inflation data surprises, with investor sentiment cautious amid geopolitical tensions affecting oil prices and bond markets.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK